-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E8MXYlXmmtRsJb5MsJ/PorDN34d2L45PZm2fKzRG7LcDT4RM7xeIEehrMw5ifVIz
 iKkuD3PC5xAx9l9PvXxifQ==

<SEC-DOCUMENT>0000950129-04-006499.txt : 20040826
<SEC-HEADER>0000950129-04-006499.hdr.sgml : 20040826
<ACCEPTANCE-DATETIME>20040826165906
ACCESSION NUMBER:		0000950129-04-006499
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20040825
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20040826
DATE AS OF CHANGE:		20040826

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBERONICS INC
		CENTRAL INDEX KEY:			0000864683
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				760236465
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19806
		FILM NUMBER:		04999524

	BUSINESS ADDRESS:	
		STREET 1:		100 CYBERONICS CENTER BLVD
		STREET 2:		SUITE 600
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77058
		BUSINESS PHONE:		(281) 228-7200

	MAIL ADDRESS:	
		STREET 1:		100 CYBERONICS  BLVD
		STREET 2:		SUITE 600
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77058
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>h18009e8vk.htm
<DESCRIPTION>CYBRONICS, INC. - DATED AUGUST 25, 2004
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">







<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D)<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B>


<P align="center" style="font-size: 10pt">Date of Report (Date of Earliest Event Reported): <B>August&nbsp;25, 2004</B>


<P align="center" style="font-size: 24pt"><B>CYBERONICS, INC.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-19806</B><BR>
(Commission<BR>
file number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>76-0236465</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>Cyberonics Building<BR>
100 Cyberonics Boulevard<BR>
Houston, Texas 77058</B><BR>
(Address of principal executive offices) (Zip code)



<P align="center" style="font-size: 10pt"><B>(281)&nbsp;228-7200</B><BR>
Registrant&#146;s telephone number, including area code:



<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">






<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;2.02&nbsp;&nbsp;Results of Operations and Financial Condition</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;9.01&nbsp;&nbsp;Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURE</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">EXHIBIT LIST</A></TD></TR>
<TR><TD colspan="9"><A HREF="h18009exv99w1.htm">Press Release dated August 25, 2004</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>






<!-- link2 "Item&nbsp;2.02&nbsp;&nbsp;Results of Operations and Financial Condition" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02</B>&nbsp;&nbsp;<B>Results of Operations and Financial Condition</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;25, 2004, Cyberonics, Inc. (&#147;Company&#148;) issued a press release
announcing that it has raised its Q2 earnings guidance from a net loss of $0.38
per share to a net loss of $0.14 per share. The Company also conducted a
conference call during which it discussed the Q2 earnings guidance and the
depression regulatory options. A copy of the press release is attached as an
exhibit.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with General Instruction B.2. of Form 8-K, the Press Release
attached hereto as Exhibit&nbsp;99.1 shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, except as shall be expressly set forth by specific reference
in such a filing.

<!-- link2 "Item&nbsp;9.01&nbsp;&nbsp;Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01</B>&nbsp;&nbsp;<B>Financial Statements and Exhibits</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">(c)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Exhibits</TD>
</TR>

<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">99.1&nbsp;&nbsp;&nbsp;&nbsp;Press Release of Cyberonics, Inc. dated as of August&nbsp;25, 2004.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>


<!-- link1 "SIGNATURE" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURE</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3"><B>CYBERONICS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000">/s/ David S. Wise
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="3">David S. Wise&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="3">Vice President, General Counsel and Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Date: August&nbsp;26, 2004


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "EXHIBIT LIST" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="center" style="font-size: 10pt"><B>EXHIBIT LIST</B>



<P align="left" style="font-size: 10pt">&nbsp;


<P align="left" style="font-size: 10pt">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release of Cyberonics, Inc. dated as of August&nbsp;25, 2004.



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>h18009exv99w1.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 25, 2004
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="h18009h1800946.gif" alt="(VNS THERAPY LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom"><B>Exhibit&nbsp;99.1</B></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><u>For Release Wednesday, August&nbsp;25, 2004; 4:00 PM EDT</u>



<P align="center" style="font-size: 10pt">CYBERONICS RAISES Q2 EARNINGS GUIDANCE AND DISCLOSES DEPRESSION REGULATORY OPTIONS<BR>
<I>Q2 Guidance Raised From a Net Loss of $0.38 per share to a Net Loss of $0.14 per share<BR>
Conference call scheduled for 4:30 PM EDT</I>

<P align="left" style="font-size: 10pt">HOUSTON, Texas, August&nbsp;25, 2004 &#151; Cyberonics, Inc. (NASDAQ:CYBX) today
announced revised guidance for the second quarter ending October&nbsp;29, 2004 and
disclosed the regulatory options available to the company to obtain FDA
approval of its Expedited Review Pre-Market Application Supplement (PMA-S) for
Vagus Nerve Stimulation (VNS)&nbsp;as an adjunctive long-term treatment for patients
with chronic or recurrent treatment-resistant depression that have failed to
respond to at least four adequate antidepressant treatments.

<P align="left" style="font-size: 10pt">&#147;We are raising our second quarter earnings guidance from a net loss of $9
million, or $0.38 per share, to a net loss of $3.4&nbsp;million, or $0.14 per
share,&#148; commented Pamela B. Westbrook, Vice President, Finance &#038; Administration
and Chief Financial Officer. &#147;We are making no changes to our sales or gross
profit margin guidance and expect Q2 net sales will be approximately $25
million and gross profit margin to be about 84%. We are raising our Q2
earnings guidance to reflect significant reductions in depression spending
resulting from the deferral of planned increases in Q2 depression spending.&#148;

<P align="left" style="font-size: 10pt">&#147;Regulations, precedents and recent dialogue with FDA suggest that there are
three depression regulatory options available to Cyberonics to obtain FDA
approval of its Expedited Review Treatment-Resistant Depression
PMA-Supplement,&#148; added Robert P. (&#147;Skip&#148;) Cummins, Cyberonics&#146; Chairman of the
Board and Chief Executive Officer. &#147;In order of priority they are (1)&nbsp;an
informal appeal process, (2)&nbsp;formal appeal processes, and (3)&nbsp;additional
studies. Our first priority is the informal appeal process to work with FDA to
determine if the concerns raised in FDA&#146;s not-approvable letter may be
addressed by existing study data. The second priority is the formal appeal
processes including a Petition of Reconsideration, a Formal Evidentiary
Hearing, and a Dispute Resolution Panel. The last resort is of course a new
randomized controlled study as requested in FDA&#146;s not-approvable letter. We
should know by calendar year-end whether the last resort is the only option
available to us.&#148;

<P align="left" style="font-size: 10pt">&#147;Cyberonics remains firmly committed to its mission to improve the lives of
people touched by pharmaco-resistant epilepsy, treatment-resistant depression
and other chronic disorders that prove to be treatable with our patented
therapy, VNS,&#148; continued Mr.&nbsp;Cummins. &#147;Cyberonics and VNS Therapy&#146;s 16&nbsp;year
track record, including seven years of worldwide commercial experience in
epilepsy, three years of commercial depression experience in Canada and Europe
and six years of depression clinical studies in the United


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">States, is a strong testament to that unwavering commitment. In the case of
depression, our mission demands that we work diligently with FDA to approve VNS
as recommended by the specially chosen Advisory Panel of experts on June&nbsp;15,
2004 to provide psychiatrists, surgeons, hospitals, payers and Americans living
with extreme treatment-resistant depression what they don&#146;t have today and
that&#146;s an informatively-labeled FDA approved safe and effective long-term
treatment option.&#148;

<P align="left" style="font-size: 10pt"><B><u>CONFERENCE CALL AND WEBCAST ACCESS INFORMATION</u></B>

<P align="left" style="font-size: 10pt">To listen to the conference call live by telephone dial 877-451-8943 (if
dialing from within the U.S.) or 706-679-3062 (if dialing from outside the
U.S.). The conference ID is 9510401; the leader is Pam Westbrook. A replay of
the conference call will be available two hours after the completion of the
conference call on Wednesday, August&nbsp;25, 2004 through Wednesday, September&nbsp;8,
2004 by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291
(if dialing outside the U.S.). The replay conference ID access code is
9510401.

<P align="left" style="font-size: 10pt">The conference call will be webcast live, and the webcast is open to the
public. To access the webcast, please enter www.cyberonics.com/webcast.
Webcast participants will need to complete a brief registration form, and in
some cases, download and install the appropriate software needed to participate
in the webcast. Please allow extra time before the webcast begins to complete
these on-line tasks. A replay of the webcast will be available on the website
www.cyberonics.com within 2 hours after the completion of the webcast and
available for one year.

<P align="left" style="font-size: 10pt"><B><u>ABOUT VNS THERAPY AND CYBERONICS</u></B>

<P align="left" style="font-size: 10pt">Cyberonics, Inc. (NASDAQ:CYBX) was founded in 1987 to design, develop and
market medical devices for the long-term treatment of epilepsy and other
chronic neurological disorders using a unique therapy, vagus nerve
stimulation (VNS). Stimulation is delivered by the VNS TherapyTM System, an
implantable generator similar to a cardiac pacemaker. The VNS Therapy
System delivers preprogrammed intermittent mild electrical pulses to the
vagus nerve 24 hours a day. The Company&#146;s initial market is epilepsy, which
is characterized by recurrent seizures. Epilepsy is the second most
prevalent neurological disorder. The Cyberonics VNS Therapy System was
approved by the FDA on July&nbsp;16, 1997 for use as an adjunctive therapy in
reducing the frequency of seizures in adults and adolescents over 12&nbsp;years
of age with partial onset seizures that are refractory to antiepileptic
medications. The VNS Therapy System is also approved for sale as a
treatment for epilepsy in all the member countries of the European Economic
Area, Canada, Australia and other markets. To date, more than 29,000
epilepsy patients in 24 countries have accumulated over 72,000 patient years
of experience using VNS Therapy. The VNS Therapy System is approved for
sale in the European Economic Area and in Canada as a treatment for
depression in patients with treatment-resistant or treatment-intolerant
major depressive episodes including unipolar depression and bipolar disorder
(manic depression). VNS Therapy is at various levels of investigational
clinical study as a potential treatment for depression, anxiety disorders,
Alzheimer&#146;s disease, and chronic headache/migraine. The Company is
headquartered in Houston, Texas and has an office in Brussels, Belgium. For
additional information please visit us at <u>www.cyberonics.com.</u>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">This press release contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended and Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. These statements can be
identified by the use of forward-looking terminology, including &#147;may,&#148;
&#147;believe,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;plan,&#148; &#147;intend,&#148; and
&#147;forecast,&#148; or other similar words. Such forward-looking statements include
statements concerning guidance for the second quarter of fiscal 2005
relating to anticipated sales, gross profit margin, operating expenses and
earnings, investments in new indication development, net income, profits and
earnings per share, maintaining and obtaining appropriate regulatory
approvals, developing VNS as a treatment for depression, the timing and
outcome of clinical studies, improving our business model, building
shareholder value, improving our productivity and efficiencies and
increasing our sales, improving our net earnings and return on equity.
Statements contained in this press release are based upon information
presently available to us and assumptions that we believe to be reasonable.
We are not assuming any duty to update this information should those facts
change or should we no longer believe the assumptions to be reasonable. Our
actual results may differ materially. Important factors that may cause
actual results to differ include, but are not limited to: continued market
acceptance of VNS Therapy and sales of our product; the development and
satisfactory completion of clinical trials and/or market test and/or
regulatory approval of VNS Therapy for the treatment of depression,
Alzheimer&#146;s disease, anxiety, or other indications; adverse changes in
coverage or reimbursement amounts by third-parties; intellectual property
protection and potential infringement claims; maintaining compliance with
government regulations and obtaining necessary government approvals for new
applications; product liability claims and potential litigation; reliance on
single suppliers and manufacturers for certain components; the accuracy of
management&#146;s estimates of future expenses and sales; and other risks
detailed in from time to time in the Company&#146;s filings with the SEC.


<P align="left" style="font-size: 10pt"><u><B><I>CONTACT INFORMATION:</I></B></u>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Pamela B. Westbrook<br>
Vice President of Finance and CFO<br>
Cyberonics, Inc.<br>
100 Cyberonics Blvd.<br>
Houston, TX 77058<br>
Main: (281)&nbsp;228-7200<br>
Fax: (281)&nbsp;218-9332<br>
<u>pbw@cyberonics.com</u>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Helen Shik<br>
Vice President<br>
Schwartz Communications<br>
230 Third Avenue<br>
Waltham, MA 02154<br>
Main: (781)&nbsp;684-0770 ext. 6587<br>
Fax: (781)&nbsp;684-6500<br>
<u>hshik@schwartz-pr.com</u></TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>h18009h1800946.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h18009h1800946.gif
M1TE&.#EAS0!>`/<``.;1*JQS8=K"V?+E'O7N])-*>OS[_.C4*8@VAL2=PNWB
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M^^;5Y/#F[Z)CG].R/=&L0.34Y+Z04,FFQ_KW^OGU^9I3=/;K&_+H\-G`U^?7
MYHT_B+)]6YQ6<_#A.+.`L+)^K_?S^-*ST+%[78U`@//G':IQI_+D'[B&5J!?
M;<^PSG\IC?OX^?CS]_/K\J1G:,JC1<NG0HP]B.#&,:5H9\.;P9]>G(P_@)E2
M<H<U@YQ9F)=/DX`LB_[^_O[]_H@VA(DWA?W\_8@WA/'C((8SB.[>(_W]_8@W
MAOW\_._?(N[>(O[]_?_^__S\_/#A(?#B(?+J\?'C'[!Y7?[__H0PBO+I\88T
MB)%'>__^_O'B(>S?Z]2S.^[?(_GP&/CS^/+C(($KB^[=)/;O]>[?(MB]J-_)
MW;:#6/[]^.W@[-_*W=>W.H8QB/[___[^_;)[78DXA,>?2-"OSO___LFA1_GX
M^;R,4^73Y)M7E^74Y,&14/#?(\2;2L6?P\RE1+.`6H@UA+%Z7_OY^X0NBMO$
MVL*73;B'M?#C((DXA?___R'Y!```````+`````#-`%X```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*$<:4!"'E:4D
M)U*\F.FNT)P.=;`(2<FSI\^&M.BDZ=3`EK^C2),FS94*3()(/Z-*1>G%0QYS
MMY1JW9I4E@8E4\.*S;@&#[^B7-.F90JFCHZQ<.,NQ'6CE0JU>/':6L(BF]R_
M<H?IN``KKV&\L%[4`<QXZIH>DG(=GISV5JXD>AIK3GFLTUW*H+FJ:+!XL^F0
MCR6'7BVZ$-C3L#528&&!M>VM*E+<B,V[HI=+GV\+1ZI"5I'>R!\N*A%\N',5
M+^(DGYY0R(7FSIU;2(&'NO>!%*YG_Q^/U$*K+M^I&V"%G;SV3B/2(Z]UH[![
M][ELQ9#?^TT#U?>1-UHF_,&V1@SM!:C="5L4N-DS?`"HH'MMS.&@9FLD8=2$
M]XU&PH6`T<)-;1P&V$8>\8$8UR*%;%BB>[`LD8:*<-421X(O.M=&$L?0*)8!
M8+B8HX!+E.9C5,,H@6->-3R058"Y2)A6$R4<*14YVT10Q9-IU1!!`!$\X$LN
M54BQ"Y=X(?!```&84896N1QAPSZ&2'%(-U7LHI8%L6!AY4_>5!*,"#BHA0(H
MG`1SA1S^^`*!(X;4X(MAN^P0!#(BL)'4+2@\H8HQO(3*"Q(9J%.`'US9DHL,
M?_8TC`\,3/^300%H;NK*.9Z8,`FJC@*1@3R%YE5I&+IDFA0"JP2#!#``B"&/
M-!\@8<T*SNBY51,7&-!J2K5P0`02'WRR`%>Y.)-!,0!L@D"C$+BA3082,(K7
ML,5J>M0"97(RQ2FNC+O`#BMP4DP+U]1ZE`4G#+(M2L+D\8HQV.0P[E8U!,#)
M!Z=@<)2C;O`"C`D\:*P6O<8>M8LICG@B32[K'N7'#CFL4`6JN#6PP<(G"=+`
M$5<`DX$-+6^ZB2&Z'/!$,QNWRTLP'W\B+U<DV^M+#1-0<\`$URAUQ`,.&(R4
M+2IH@+-)T:B``A/]?$#%Q$FA,`0GV$@A,KM`'&`%`\5\H(X?7OO_$_51"#A`
M!34,!#`W952.31(MD!3F``"\7!%L4@[LD^LDXB#5ZP')#!'MKT\K];<_E@5`
M#2_GS++:B00H+A(M:=CCSQ$2%)/!#I,BE<L#!R`!@"NYTWW`%WX\,06I$AR.
MU.C^^#'$`9X<X'3?:;51"'JN@U3+'4:AT(@N'TA@[5%'1'#Q*:%O_L4R1S`!
M#!(@AV[R#L26[`\"-73C"##82&/#^(;ADY^R]Y%:D&%#1Y`&$AA0`Z3<PA5:
M,,8!;,`VX7VA#+=H'P",80(B(`!-S+N?*^JQ06!,X0H3:`0`TV(!60B`@`4L
MP8;.YHD,)(-M.QA`W)2GOC<=Q08FR-LY_S"X//K52RL(*(`5CC>J#)SC5'B!
MCG1@V)%:S`%`KH!<..3E@$1<;H4]1(HYS'"N#%CA:2$\5@$2`8!B\,(8A9.?
M4J1(Q2I>$2DUD$<Q3%`%7]SB`0SP'?"4$D:D=&H*>XS7_.IG+ZZH:0(,,`:Z
M-*$ZT43G(+3HQ3]H00N!X`(7!,$'/@2BC%H,@Y,"$00H"8*+6FQ2D\_X!3$Z
M*8Q?/.,?O>AD+O^!"P-HLB#X<&4MB/&+5Z:RD_C0I2X%\DN!X&,8FR0&,32Y
MRTTNHI.\Q&8S"5*+2[CH".5`Q@?8L8LC/.%\<BSD43+HOCVR0V-IW,H""G`*
M3GCB"G^@F59:>/\<@P@!$ETX@P<$PH50#,0)@&"!$_YA!`$P0Q]G^`<D^!&'
M%`ED`]+!@I]`(`,-O(4$)=B#1".:!O0`@A]\P*9`%,$/D6[A`JP8`3Y"T3H7
ME.(?+GC#/[@`EGD8X1_SV`E#[Q"?-;C@`MSXQP]@\`\O`,(%'0`+#.[@2E:H
M=""UZ("0LL@L<SA`&AQL1-`T!X&Z75`KOGB>,3"VBY<QTC`+>(`$W("-1$2!
M*]O9S4'.H`$\0.$?T2!!#_@@44C\@P#'J$4V(`$#`>R&KU`A""0`(8`B^(D/
M&I`!'?Y!`C+<0%LD2`,W&/$/%I`!>P,AP3QZ]`\.;'81/]"I&A1Q@R3_*.`?
M&P!+`OR2@)^V-@$*Z"0CTD"!?]2!J3(@[3_N@`MF)"`&:Y#!5052BP0(J082
M,$8&`E``9,1-CA;TH5)R`0H3K+4%LS"B_?`BAR=8HP_T$`5>6P$'A,`@!J6)
M0Q:R0"`!&):O[U@$8QW[CU\0X`<-&@@70'`#->CC'UC@AA<$0@(6;/8?<;@$
M]GYP6X+08B5I8$9K7_N#;"S""7?H0!J@X@00_&.W+_XI(TK``@U,>+C%/>Z+
M=5I:7,"`!#H`A`:FN\E,V.<H*-B!)Z8@C0GD2A,K3)I9Q:L5,WS`=A*H0CR.
M>)0X5:`&!BL#*`[@"#',PFMM`,.%#X((/[TA_PY*T($'1!P*#6A@H?]`Z#S>
MD6=^_(`0!.&"GWJPT$C(@!6`YH(+\+`39J2APRR(`0BNRHH.."$^KOT';*N!
MA3T((!.1\(`7")!9$DPX"])QP6TUH-,1$->X3!5"!]#1`841@@2T4$`'B#P,
M+!SY*`ZX`A*F$$@`."!X25&G4K)B"FP4XP`B.``TC/5(`*B"$OI$BAS&4`Q.
MJ*.12L'6*!&"2F'\LA?"$`@F2$$0(4SX'[400G$)LDM:K*$6REC#*-*-BU[,
M4B`46*6^M_D/`PAAE?^F13%QD4D#*%P@:Q""*_\A"&UIJ\"N?'B!55J*B]-B
ME?,V2#9J=81D("-4'_]H`9637=;AK7Q39S-!$((1C&)0>Q/L<`/(*HF4P/&@
M;A.0[[7(D!`O,$.Y=80(+MPA):Y.PP00&"O+IYRFY[G1YO9RG@D&4+BY(<`<
MFM`%)\)1`:1I!1:I4$1"=$`"%R<=(@84DC^P"XWOID79CBQO,;`..`?H[]D\
M>``.<M$(&A0#&@!(1M:VLIT0)`0&?%C#VR%""RY@QWL#R(`FS+X5O)/+#A_@
M\OTJT((^\$(;'V```&@.OW?V;4<B1H@^YH&)R4.D%'+W1[`/T+6[M_RL><G*
M*L*P7@2XXA/1$E4P@J"*"(`7*6U0@T)`4%_;/P07G9![^UJ0.;4XP!2@<(;_
MU/$R!BO<=;P5>,(7J/")``S!`>-/RFBXH!!]&-;Z#J'%C;1RA#XJ"`4U("6V
ML2,WA1!Z4`>O@7\-P0A+0#U#8ANYH`*`H!"$H`],I8`-@0LL\&L/J!WN,`,*
M40=JAX$.H0,.F!8.,`244`4(@`(/4`%34P`?Y`"4L((+D`LUT`@%`"`X6`'K
MDD$%\`<U@`"^L`D%L`N;X`P/T`C.X``/@`!M8`D+`0<)1H(,@0L:L"0H:`I:
MX`P+X``1$`C+T`CR@`$+T`B'4`55L``+\`<T8`HM(`>W@``5P`[R(%_S-`G)
MT`T1<`U50`5V$`'LX"63``\V<`TGP&<)P04E\!96_]@0;]"`H($`SF!FM^``
M`2`/=G`/^V"&C1`.3``*.-"&^^`,^_!!_W((@;"&\]0YJS`)&.`'=J`*B=`D
MH``*3U``.-`!"H$/.E"`CWB%BJ"%6T&)EHB)J(`&5)`\9[@"8V`#.+`+?\``
M6F`#9>`+:X(&-I`(U[``SI`(*Q`(C>*-5#`!/.</YI&`!Q$-+#!%P<@0C!`+
MN:<6QGAF8"B&9(@!"``!J7,O$*`%`0"+9V@($H`*IU`#NU``]3`&/J0F`?`%
M<X-V'*`0M/`.[?".#F$CQ#A>#^`T<V<#3Y"0FE`&260%:&`*)%D`$_``*YE6
M:(`!#F`&3)`/%;`*.V`MOO\0DW9`,[D`"Y9P<0B!#T7P8!C9$&N@!AS8@9.1
M9K&7$"[`#T7Y$$;@#O.HE'OB0@NQ""#@B%')$+2@!Y)P@E:)%+`@"2[`$"Y@
M(5V9D7A0E6.9%+:``KRX$""@#T2VE@E!"X.P!`+XEEUF"Y:0;E.H5WB9D5C`
MEWXY7K9P"<6T$$,Q#H5)>>_P'XG99?Z0!:ND$'Q0!)(7F1`Q#-'@#K+CE[8@
M"7?@$!Z0`)XY$=EP"2CPEK:0`GBV$+30`ZJYFA-1"UN0`J,Y)+:0"ATP;@MA
M!'$`#KAI$4+``F*9';`0"]V1@81@6<=I$;40"4FPD;<!"PW``<+)$&=0`HHX
MG1;_@0MX4`C8"1JVT`!WP&,.(0`RD`[BJ1&XP`=I<`))&1I[D07<X!</40T"
M0`+?$)\=(0R1P`\O<)]XD0M+,`<>8%$/(03M4`0B):`?@0M*4`>6T`J(R14H
M(`MYP`KOT)D3(0"6`(P4*A(&<`SOH`\>L`%<P`5%,`/?P`C*<!%&<`>G>:+?
M,0,LP`P.JJ.]80!.,`]`ZAU8<%J^5:2]P0SSH`@Z`)1*:B"A8`G9`&A1"AL$
M@`7Z]0;1<*6P\0BA4`<<$*!>NAFXH`!%D``=$`E=6J:`40OK0`>0X`&7@`<3
M*51N.A50@`=&4`2E4%)DL`=@$`EW8`"HE:=BH0"9D`T;$>`%W%`+[(FHDCJI
(E%JIFQ$0`#L_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
